This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.
Dow 30 Stock Roundup: GE Cuts Dividend, Wal-Mart, Home Depot Beat
by Swarup Gupta
The Dow traversed a tense week, suffering losses on two consecutive days after a key component cut its dividend significantly.
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis
by Zacks Equity Research
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II
by Zacks Equity Research
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Stock Market News For Nov 13, 2017
by Zacks Equity Research
Markets finished in the red on Friday after market watchers speculated about the likely outcome of a delay in tax reforms, proposed last Thursday by the Senate Finance Committee.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.
Top Research Reports for Merck, UPS & Caterpillar
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), UPS (UPS), and Caterpillar (CAT).
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
by Zacks Equity Research
AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
by Zacks Equity Research
Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.
Dow 30 Stock Roundup: Chevron, Exxon, Apple Earnings Impress
by Swarup Gupta
The Dow continued to notch up gains during a week marked by key legislative developments.
Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.
Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak
by Zacks Equity Research
Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
by Zacks Equity Research
Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.
Stock Market News For Oct 31, 2017
by Zacks Equity Research
Benchmarks ended in the red on Monday following reports from Bloomberg that the House was considering a ???gradual phasing-in??? of corporate tax rates.
What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
by Zacks Equity Research
The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.
Stock Market News For Oct 30, 2017
by Zacks Equity Research
The S&P 500 and the Nasdaq notched up record closes following splendid quarterly earnings from some of the major tech stocks.
Data and Earnings Deluge
by Zacks Equity Research
Data and Earnings Deluge
Q3 GDP Hits 3.0%, Q3 Earnings Take Pre-Market Higher
by Mark Vickery
We get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2???s final read of 3.1%.
Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat
by Zacks Equity Research
Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.
Merck (MRK) Tops on Q3 Earnings, Ups View Despite Sales Miss
by Zacks Equity Research
Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its 2017 adjusted earnings guidance while raising its sales guidance marginally.
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings top estimates while revenues match the same. However, the bottom was flat at constant exchange rates (CER).